Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Single-Dose, Open-Label, Parallel-Group Study in Healthy Volunteers to Assess the Relative Bioavailability of a Subcutaneous Dose of Nemolizumab When Administered With Auto-Injector Compared to Dual-Chamber Syringe

NCT05405985 is registered in ClinicalTrials.gov with Galderma R&D as lead sponsor.

NCT NCT05405985
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05405985 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Single-Dose, Open-Label, Parallel-Group Study in Healthy Volunteers to Assess the Relative Bioavailability of a Subcutaneous Dose of Nemolizumab When Administered With Auto-Injector Compared to Dual-Chamber Syringe
Lead sponsor
Galderma R&D
Phase
Phase 1
Overall status
Completed
Start date
August 11, 2022
Completion date
December 8, 2022
Enrollment
192 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers